MSB Share Price

Open 1.23 Change Price %
High 1.24 1 Day 0.01 0.82
Low 1.21 1 Week 0.04 3.36
Close 1.23 1 Month 0.11 9.82
Volume 298585 1 Year -0.31 -20.13
52 Week High 3.03
52 Week Low 1.01
MSB Important Levels
Resistance 2 1.26
Resistance 1 1.25
Pivot 1.23
Support 1 1.21
Support 2 1.20
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
AKK 0.01 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
NMI 0.02 100.00%
NMI 0.02 100.00%
NMI 0.02 100.00%
RXL 0.02 100.00%
RXL 0.02 100.00%
RXL 0.02 100.00%
GBZ 0.02 100.00%
ARA 0.57 54.05%
ARA 0.57 54.05%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
RMG 0.01 -50.00%
RMG 0.01 -50.00%
XST 0.01 -50.00%
XST 0.01 -50.00%
EXG 0.02 -33.33%
More..

Mesoblast Ltd (ASX: MSB)

MSB Technical Analysis 2
As on 8th Dec 2016 MSB Share Price closed @ 1.23 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.56 & Buy for SHORT-TERM with Stoploss of 1.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
MSB Target for December
1st Target up-side 1.37
2nd Target up-side 1.48
3rd Target up-side 1.59
1st Target down-side 1.05
2nd Target down-side 0.94
3rd Target down-side 0.83
MSB Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.mesoblast.com
MSB Address
MSB
55 Collins Street
Level 39
Melbourne, VIC 3000
Australia
Phone: 61 3 9639 6036
Fax: 61 3 9639 6030
MSB Latest News
Interactive Technical Analysis Chart Mesoblast Ltd ( MSB ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Mesoblast Ltd
MSB Business Profile
Mesoblast Limited, a clinical development company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include its Mesenchymal Precursor Cell (MPC) technology platform, which is used to develop products derived from bone marrow and adipose tissue sources; Dental Pulp Stem Cells technology; and expanded Hematopoietic Stem Cells technology. It develops products for intravenous administration to target unmet medical needs in diseases of excessive inflammation and immune dysfunction, including type 2 diabetes, inflammatory joint diseases, and inflammatory lung diseases; MPC treatment therapies for diseases of the spine; adult stem cell-based therapies for the treatment of cardiovascular diseases, including congestive heart failure; and products for treating eye diseases, neurologic diseases, and cord blood expansion. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPC products in various diseases, including cardiovascular diseases and neurologic conditions. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.